ReviewAnnual review of immunology2016
Genomics of Immune Diseases and New Therapies.
Review in Annual review of immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An Updated Review on MSMD Research Globally and A Literature Review on the Molecular Findings, Clinical Manifestations, and Treatment Approaches in China.Frontiers in immunology · 2022Pooled it
- FAS and FASL expression in autoimmune lymphoproliferative syndrome and immune thrombocytopenia: limited diagnostic utility as transcriptional biomarkers.Molecular biology reports · 2026Article
- Effects of two different variants in theFrontiers in immunology · 2025Article
- Immune Diseases: Challenges, Hopes and Recent Achievements.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Cross-population applications of genomics to understand the risk of multifactorial traits involving inflammation and immunity.Cambridge prisms. Precision medicine · 2024Review
- Article
- Integrative multi-omics approaches to explore immune cell functions: Challenges and opportunities.iScience · 2023Review
- GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans.The Journal of experimental medicine · 2022Article
- Druggable monogenic immune defects hidden in diverse medical specialties: Focus on overlap syndromes.World journal of clinical pediatrics · 2022Review
- Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival.mBio · 2021Article
- Aryl hydrocarbon receptor (Ahr)-dependent Il-22 expression by type 3 innate lymphoid cells control of acute joint inflammation.Journal of cellular and molecular medicine · 2021Article
- One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency.Frontiers in immunology · 2021Article
- Article
- XMEN: welcome to the glycosphere.The Journal of clinical investigation · 2020Article
- Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis.Nature communications · 2019Article
- The Collaborative Cross: A Systems Genetics Resource for Studying Host-Pathogen Interactions.Cell host & microbe · 2019Review
- Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies.Frontiers in immunology · 2019Article
- Exploring the RNA Gap for Improving Diagnostic Yield in Primary Immunodeficiencies.Frontiers in genetics · 2019Review
- Common variable immune deficiency: Dissection of the variable.Immunological reviews · 2019Review
- Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort.Clinical & translational immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Genomic DNA sequencing technologies have been one of the great advances of the 21st century, having decreased in cost by seven orders of magnitude and opening up new fields of investigation throughout research and clinical medicine. Genomics coupled with biochemical investigation has allowed the molecular definition of a growing number of new genetic diseases that reveal new concepts of immune regulation. Also, defining the genetic pathogenesis of these diseases has led to improved diagnosis, prognosis, genetic counseling, and, most importantly, new therapies. We highlight the investigational journey from patient phenotype to treatment using the newly defined XMEN disease, caused by the genetic loss of the MAGT1 magnesium transporter, as an example. This disease illustrates how genomics yields new fundamental immunoregulatory insights as well as how research genomics is integrated into clinical immunology. At the end, we discuss two other recently described diseases, CHAI/LATAIE (CTLA-4 deficiency) and PASLI (PI3K dysregulation), as additional examples of the journey from unknown immunological diseases to new precision medicine treatments using genomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.